FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008558092> ?p ?o ?g. }

• W3008558092 endingPage "687" @default.
• W3008558092 startingPage "687" @default.
• W3008558092 abstract "687 Background: Patients (pts) with brain metastasis from renal cell carcinoma (RCC) have poor prognosis and are often excluded from randomized registrational trials. The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) for A+Ax vs S in pts with advanced RCC (Motzer NEJM 2019). The activity of A+Ax in pts with brain metastasis enrolled in JAVELIN Renal 101 is presented. Methods: PFS was compared between treatment arms for the subgroup of pts randomized in JAVELIN Renal 101 with brain metastases at enrollment (pts with brain disease site prior to randomization by blinded independent central review [BICR] or by investigator assessment). PFS time was summarized per BICR assessment by treatment arm using the Kaplan-Meier method. The Cox proportional hazards model was fitted to compute the hazard ratio (HR) and the corresponding CI. In addition, time to brain metastasis was assessed for pts without brain metastasis by BICR at enrollment after treating death as a competing risk. Results: Of all randomized pts (A+Ax arm, N=442; S, N=444), 23 in each arm (5.2%) had asymptomatic brain metastasis at enrollment; of these, pts assigned to A+Ax had a PFS of 4.9 mo (95% CI: 1.6, 5.7) vs 2.8 mo (95% CI: 2.3, 5.6) for pts assigned to S (HR: 0.90; 95% CI: 0.43, 1.88). Among pts without brain metastasis at enrollment, 8 pts on the A+Ax arm and 10 on the S arm developed brain metastasis during the trial, based on BICR assessment; 17/18 occurred ≤12 mo from randomization. The cumulative incidence rate of brain metastasis at 18 mo was 2% (95% CI: 0.6, 3.3) for the A+Ax arm and 3% (95% CI: 1.1, 4.8) for the S arm. Conclusions: In this post hoc exploratory analysis of JAVELIN Renal 101, the observed PFS among pts with brain metastasis at enrollment was similar between the two arms, with HR and median PFS numerically favoring A+Ax. Pts on the S arm had a numerically higher incidence of new brain metastases on trial. Outcomes are poor in pts with advanced RCC and brain metastasis; more effective treatments are needed. Clinical trial information: NCT02684006." @default.
• W3008558092 created "2020-03-06" @default.
• W3008558092 creator A5004247363 @default.
• W3008558092 creator A5006337629 @default.
• W3008558092 creator A5007689146 @default.
• W3008558092 creator A5009171545 @default.
• W3008558092 creator A5009282743 @default.
• W3008558092 creator A5016654748 @default.
• W3008558092 creator A5017136846 @default.
• W3008558092 creator A5020353650 @default.
• W3008558092 creator A5025529463 @default.
• W3008558092 creator A5037677450 @default.
• W3008558092 creator A5046444872 @default.
• W3008558092 creator A5051429729 @default.
• W3008558092 creator A5051480361 @default.
• W3008558092 creator A5052504518 @default.
• W3008558092 creator A5059063118 @default.
• W3008558092 creator A5071984747 @default.
• W3008558092 creator A5074162105 @default.
• W3008558092 creator A5076054848 @default.
• W3008558092 date "2020-02-20" @default.
• W3008558092 modified "2023-10-17" @default.
• W3008558092 title "Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S)." @default.
• W3008558092 doi "https://doi.org/10.1200/jco.2020.38.6_suppl.687" @default.
• W3008558092 hasPublicationYear "2020" @default.
• W3008558092 type Work @default.
• W3008558092 sameAs 3008558092 @default.
• W3008558092 citedByCount "9" @default.
• W3008558092 countsByYear W30085580922020 @default.
• W3008558092 countsByYear W30085580922021 @default.
• W3008558092 countsByYear W30085580922022 @default.
• W3008558092 countsByYear W30085580922023 @default.
• W3008558092 crossrefType "journal-article" @default.
• W3008558092 hasAuthorship W3008558092A5004247363 @default.
• W3008558092 hasAuthorship W3008558092A5006337629 @default.
• W3008558092 hasAuthorship W3008558092A5007689146 @default.
• W3008558092 hasAuthorship W3008558092A5009171545 @default.
• W3008558092 hasAuthorship W3008558092A5009282743 @default.
• W3008558092 hasAuthorship W3008558092A5016654748 @default.
• W3008558092 hasAuthorship W3008558092A5017136846 @default.
• W3008558092 hasAuthorship W3008558092A5020353650 @default.
• W3008558092 hasAuthorship W3008558092A5025529463 @default.
• W3008558092 hasAuthorship W3008558092A5037677450 @default.
• W3008558092 hasAuthorship W3008558092A5046444872 @default.
• W3008558092 hasAuthorship W3008558092A5051429729 @default.
• W3008558092 hasAuthorship W3008558092A5051480361 @default.
• W3008558092 hasAuthorship W3008558092A5052504518 @default.
• W3008558092 hasAuthorship W3008558092A5059063118 @default.
• W3008558092 hasAuthorship W3008558092A5071984747 @default.
• W3008558092 hasAuthorship W3008558092A5074162105 @default.
• W3008558092 hasAuthorship W3008558092A5076054848 @default.
• W3008558092 hasConcept C121608353 @default.
• W3008558092 hasConcept C126322002 @default.
• W3008558092 hasConcept C126894567 @default.
• W3008558092 hasConcept C143998085 @default.
• W3008558092 hasConcept C168563851 @default.
• W3008558092 hasConcept C204243189 @default.
• W3008558092 hasConcept C207103383 @default.
• W3008558092 hasConcept C2777472916 @default.
• W3008558092 hasConcept C2778164965 @default.
• W3008558092 hasConcept C2779013556 @default.
• W3008558092 hasConcept C2779490328 @default.
• W3008558092 hasConcept C44249647 @default.
• W3008558092 hasConcept C71924100 @default.
• W3008558092 hasConceptScore W3008558092C121608353 @default.
• W3008558092 hasConceptScore W3008558092C126322002 @default.
• W3008558092 hasConceptScore W3008558092C126894567 @default.
• W3008558092 hasConceptScore W3008558092C143998085 @default.
• W3008558092 hasConceptScore W3008558092C168563851 @default.
• W3008558092 hasConceptScore W3008558092C204243189 @default.
• W3008558092 hasConceptScore W3008558092C207103383 @default.
• W3008558092 hasConceptScore W3008558092C2777472916 @default.
• W3008558092 hasConceptScore W3008558092C2778164965 @default.
• W3008558092 hasConceptScore W3008558092C2779013556 @default.
• W3008558092 hasConceptScore W3008558092C2779490328 @default.
• W3008558092 hasConceptScore W3008558092C44249647 @default.
• W3008558092 hasConceptScore W3008558092C71924100 @default.
• W3008558092 hasIssue "6_suppl" @default.
• W3008558092 hasLocation W30085580921 @default.
• W3008558092 hasOpenAccess W3008558092 @default.
• W3008558092 hasPrimaryLocation W30085580921 @default.
• W3008558092 hasRelatedWork W1521450242 @default.
• W3008558092 hasRelatedWork W2013700616 @default.
• W3008558092 hasRelatedWork W2154171266 @default.
• W3008558092 hasRelatedWork W2154205092 @default.
• W3008558092 hasRelatedWork W2168890198 @default.
• W3008558092 hasRelatedWork W2170584913 @default.
• W3008558092 hasRelatedWork W2384668898 @default.
• W3008558092 hasRelatedWork W2551353941 @default.
• W3008558092 hasRelatedWork W2996164021 @default.
• W3008558092 hasRelatedWork W3151554875 @default.
• W3008558092 hasVolume "38" @default.
• W3008558092 isParatext "false" @default.
• W3008558092 isRetracted "false" @default.
• W3008558092 magId "3008558092" @default.
• W3008558092 workType "article" @default.